[Skip to Content]
[Skip to Content Landing]
December 7, 2011

Androgen Deprivation Therapy and Competing Risks

Author Affiliations

Author Affiliations: Departments of Medical Oncology (Dr Kelly) and Urology (Drs Kelly and Gomella), Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania.

JAMA. 2011;306(21):2382-2383. doi:10.1001/jama.2011.1791

Androgen deprivation therapy (ADT) has been the mainstay for the treatment of advanced prostate cancer for the past 7 decades. Surgical castration (orchiectomy) and the use of estrogens have been largely replaced by the administration of gonadotropin-releasing hormone (GnRH) agonists as the most common form of ADT used today.1,2 GnRH agonists are relatively easy to administer, avoid the well-known cardiovascular risks of estrogens and the psychological trauma of surgical castration, and allow the potential for the androgen blockade to be reversed.1,2